000			04014nam a22003375i 4500
999			_c76402 _d76402 _x1
001			76402
003			ES-MaUEC
005			20230202102040.0
007			cr nn 008mamaa
008			130810s2013 gw | s |||| 0|eng d
020			_a9783642179075
024	7		_a10.1007/978-3-642-17907-5 _2doi
040			_bspa _dES-MaUEC
050		4	_aRS420 _b.K543 2013
100	1		_aKlebe, Gerhard _eeditor literario _0Local _985455
245	1	0	_aDrug Design : _bMethodology, Concepts, and Mode-of-Action _cedited by Gerhard Klebe.
260			_aBerlin, Heidelberg _bSpringer International Publishing _c2013
300			_a1 recurso en línea (XV, 901 p.) _b496 ilustraciones, 333 ilustraciones en color eReference.
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aPart I Â{u6D6E}ndamentalsin Drug Research -- 1. Drug Research Yesterday, Today and Tomorrow -- 2. The Role of Serendipityin Drug Research -- 3. Classical Drug Research -- 4. Proteinâ€{uCA67}and Interactionsas the Basis for Drug Action -- 5. Optical Activity and Biological Effects -- Part II Discovery and Optimizationof Lead Compounds -- Â{u6BA0}Screeningfor Lead Structures -- 7.Â{u04E3}reening Technologies for LeadDiscovery -- 8. Optimizationof Lead Structures -- 9. Designingprodrugs -- 10. Peptidomimetics -- Part III Â{u5E30}perimental and Theoretical Methods -- 11. Combinatorics: Chemistry With Big Numbers -- 12. Gene Technology in drug research -- Â{u1CEE} Experimental Methods of Structure Determination -- 14. The Spatial Structure of Biomolecules -- 15. Molecular Modelling -- 16. Conformational Analysis -- Part IV Structureâ€{u18F4}ivity Relationships and Design Approaches -- 17.Pharmacophore Hypothesis and Molecular Comparisons -- 18. Quantitative Structureâ€{u18F4}ivityRelationships -- 19.Â{u01B2}om in vitro to in vivo:Optimization of ADME-Tox Properties -- 20. ProteinModeling and Structure-BasedDrug Design -- 21.Â{u0043}ase Study: Structure-Based Inhibtor Design for tRNA-Guanine Transglycosylase -- Part V. Drugs and drug action: Successes of stucture-based design -- 22. Howdrugs act: Concepts for therapy -- 23. Inhibitors of hydrolases With an acyl-enzymeintermediate -- 24. Asparticprotease inhibitors -- 25. Inhibitorsof hydrolysing metalloenzymes -- 26. Inhibitorsof transferases -- 27. Inhibitors ofoxidoreductases -- 28.Â{u0067}onists and antagonistsof nuclear receptors -- 29. Agonists and antagonists of membrane-bound -- 30. Ligands forchannels, pores and transporters -- 31. Ligands for surfacereceptors -- 32. Biologicals: Peptides, proteins, nucleotidesand macrolides as drugs.
520			_aUnique work on structure-based drug design, covering multiple aspects of drug discovery and development. Fully colored, many images, computer animations of 3D structures (these only in electronic form). Makes the spatial aspects of interacting molecules clear to the reader, covers multiple applications and methods in drug design. Structures by mode of action, no therapeutic areas. Of high relevance for academia and industrial research. Focus on gene technology in drug design, omics-technologies computational methods experimental techniques of structure determinationÂ{uDD6C}tiple examples on mode of action of current drugs, ADME-tox properties in drug development, QSAR methods, combinatorial chemistry, biologicals, ribosome, targeting protein-protein interfaces.
650		7	_2embne _9395061 _aMedicamentos _xDiseño
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-642-17907-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12820209 _b10-10-17 _c01-10-14
942			_2lcc _cLE
945			_aRS420 .K543 2013 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11549427 _z06-04-17
988			_aEBSPRINGER
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0